GoldenGolden
Advanced Search
Novo Nordisk

Novo Nordisk

Novo Nordisk is a danish company founded in 1923 by David Thompson, August Krogh and Hans Christian Hagedorn.

Novo Nordisk is a healthcare company that was founded in 1923 and headquartered outside Copenhagen, Denmark. The company's purpose is to drive change to tackle diabetes and many other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases.

The company operates by pioneering scientific breakthroughs, expanding access to its medicines and working haard to prevent and cure the diseases it treats.

The company focuses on the serious chronic diseases that affect several millions of people, by addressing one of the most urgent global health challenges.

By combining its innovation and commercial excellence, the company draws upon insights from patients and partners to revolutionalize bold ideas into life-saving and preventive medicines.

The company makes long-term investments in novel treatments and technologies, including curative stem cell-based therapies, to advance the development of digital health solutions and medical devices.

Timeline

June 11, 2020
Novo Nordiska acquires U.S.-based Corvidia Therapeutics, a portfolio company of Sofinnova Partners, a European venture capital firm.

2019
Novo Nordisk launches its connected insulin pens, the NovoPen 6 and NovoPen Echo Plus

Patents

Products

People

Name
Role
LinkedIn

Abdullah Al Ramahi

Employee

Agnes Degroote

Employee

Alfonso R. Escobar Peñalver

Employee

Amine Kadiri

Employee

Anne Mette Carstensen

Employee

...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Conor Hale
September 27, 2021
FierceBiotech
Biocorp's Mallya digital device clips directly onto prefilled insulin injectors and logs delivery amounts and times by linking to a smartphone via Bluetooth.
Nick Paul
July 12, 2021
FierceBiotech
Novo Nordisk has struck a $1.2 billion deal to buy Prothena's ATTR amyloidosis program. The deal will see Novo pay $100 million in upfront and near-term fees for worldwide rights to the phase 2 ready anti-amyloid immunotherapy PRX004.
Paige Minemyer
June 28, 2021
FierceHealthcare
Walmart is launching its first-ever private label insulin analog, which will be made available exclusively at its stores.
Amirah Al Idrus
June 28, 2021
FierceBiotech
Hanmi Pharmaceuticals may no longer have a diabetes partner in Sanofi, but newly released results for its GLP-1 drug could move the needle for Type 2 diabetes patients with a history of cardiovascular disease, kidney disease or both. Efpeglenatide reduced their risk of heart attack, stroke and death and also slowed decline in patients' kidney function, new data show.
American Diabetes Association
June 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- The American Diabetes Association® (ADA), along with the nation's leading diabetes organizations, unveiled Let's Talk Insulin today, a campaign...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.